Selected research
Industry Research
Pharmaceutical Excipient Albumin Industry Research Report 2026
Market perspective
The global Pharmaceutical Excipient Albumin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Pharmaceutical Excipient Albumin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Pharmaceutical Excipient Albumin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Pharmaceutical Excipient Albumin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Pharmaceutical Excipient Albumin include CSL, Albumedix, Biotest, CBPO, HiMedia, Hualan Bio, Kedrion, LFB Group and Octapharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Pharmaceutical Excipient Albumin market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pharmaceutical Excipient Albumin Market by Company
CSL
Albumedix
Biotest
CBPO
HiMedia
Hualan Bio
Kedrion
LFB Group
Octapharma
Ventria (InVitria)
Grifols
Merck
Shanghai RAAS
Takeda
Pharmaceutical Excipient Albumin Segment by Type
Human Serum Albumin
Recombinant Albumin
Pharmaceutical Excipient Albumin Segment by Application
Cell Culture Media
Medical Supplements
Pharmaceutical Excipient Albumin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmaceutical Excipient Albumin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pharmaceutical Excipient Albumin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmaceutical Excipient Albumin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pharmaceutical Excipient Albumin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pharmaceutical Excipient Albumin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pharmaceutical Excipient Albumin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Human Serum Albumin
- Recombinant Albumin
Applications
- Cell Culture Media
- Medical Supplements
Companies covered
- CSL
- Albumedix
- Biotest
- CBPO
- HiMedia
- Hualan Bio
- Kedrion
- LFB Group
- Octapharma
- Ventria (InVitria)
- Grifols
- Merck
- Shanghai RAAS
- Takeda
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Pharmaceutical Excipient Albumin Market Size (2021-2032)
- 2.2.2 Global Pharmaceutical Excipient Albumin Sales (2021-2032)
- 2.2.3 Global Pharmaceutical Excipient Albumin Market Average Price (2021-2032)
- 2.3 Pharmaceutical Excipient Albumin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Human Serum Albumin
- 2.3.3 Recombinant Albumin
- 2.4 Pharmaceutical Excipient Albumin by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Cell Culture Media
- 2.4.3 Medical Supplements
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Pharmaceutical Excipient Albumin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Pharmaceutical Excipient Albumin Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Pharmaceutical Excipient Albumin Revenue of Manufacturers (2021-2026)
- 3.4 Global Pharmaceutical Excipient Albumin Average Price by Manufacturers (2021-2026)
- 3.5 Global Pharmaceutical Excipient Albumin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Pharmaceutical Excipient Albumin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pharmaceutical Excipient Albumin, Product Type & Application
- 3.8 Global Manufacturers of Pharmaceutical Excipient Albumin, Established Date
- 3.9 Global Pharmaceutical Excipient Albumin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 CSL
- 4.1.1 CSL Company Information
- 4.1.2 CSL Business Overview
- 4.1.3 CSL Pharmaceutical Excipient Albumin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 CSL Pharmaceutical Excipient Albumin Product Portfolio
- 4.1.5 CSL Recent Developments
- 4.2 Albumedix
- 4.2.1 Albumedix Company Information
- 4.2.2 Albumedix Business Overview
- 4.2.3 Albumedix Pharmaceutical Excipient Albumin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Albumedix Pharmaceutical Excipient Albumin Product Portfolio
- 4.2.5 Albumedix Recent Developments
- 4.3 Biotest
- 4.3.1 Biotest Company Information
- 4.3.2 Biotest Business Overview
- 4.3.3 Biotest Pharmaceutical Excipient Albumin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Biotest Pharmaceutical Excipient Albumin Product Portfolio
- 4.3.5 Biotest Recent Developments
- 4.4 CBPO
- 4.4.1 CBPO Company Information
- 4.4.2 CBPO Business Overview
- 4.4.3 CBPO Pharmaceutical Excipient Albumin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 CBPO Pharmaceutical Excipient Albumin Product Portfolio
- 4.4.5 CBPO Recent Developments
- 4.5 HiMedia
- 4.5.1 HiMedia Company Information
- 4.5.2 HiMedia Business Overview
- 4.5.3 HiMedia Pharmaceutical Excipient Albumin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 HiMedia Pharmaceutical Excipient Albumin Product Portfolio
- 4.5.5 HiMedia Recent Developments
- 4.6 Hualan Bio
- 4.6.1 Hualan Bio Company Information
- 4.6.2 Hualan Bio Business Overview
- 4.6.3 Hualan Bio Pharmaceutical Excipient Albumin Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hualan Bio Pharmaceutical Excipient Albumin Product Portfolio
- 4.6.5 Hualan Bio Recent Developments
- 4.7 Kedrion
- 4.7.1 Kedrion Company Information
- 4.7.2 Kedrion Business Overview
- 4.7.3 Kedrion Pharmaceutical Excipient Albumin Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Kedrion Pharmaceutical Excipient Albumin Product Portfolio
- 4.7.5 Kedrion Recent Developments
- 4.8 LFB Group
- 4.8.1 LFB Group Company Information
- 4.8.2 LFB Group Business Overview
- 4.8.3 LFB Group Pharmaceutical Excipient Albumin Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 LFB Group Pharmaceutical Excipient Albumin Product Portfolio
- 4.8.5 LFB Group Recent Developments
- 4.9 Octapharma
- 4.9.1 Octapharma Company Information
- 4.9.2 Octapharma Business Overview
- 4.9.3 Octapharma Pharmaceutical Excipient Albumin Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Octapharma Pharmaceutical Excipient Albumin Product Portfolio
- 4.9.5 Octapharma Recent Developments
- 4.10 Ventria (InVitria)
- 4.10.1 Ventria (InVitria) Company Information
- 4.10.2 Ventria (InVitria) Business Overview
- 4.10.3 Ventria (InVitria) Pharmaceutical Excipient Albumin Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Ventria (InVitria) Pharmaceutical Excipient Albumin Product Portfolio
- 4.10.5 Ventria (InVitria) Recent Developments
- 4.11 Grifols
- 4.11.1 Grifols Company Information
- 4.11.2 Grifols Business Overview
- 4.11.3 Grifols Pharmaceutical Excipient Albumin Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Grifols Pharmaceutical Excipient Albumin Product Portfolio
- 4.11.5 Grifols Recent Developments
- 4.12 Merck
- 4.12.1 Merck Company Information
- 4.12.2 Merck Business Overview
- 4.12.3 Merck Pharmaceutical Excipient Albumin Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Merck Pharmaceutical Excipient Albumin Product Portfolio
- 4.12.5 Merck Recent Developments
- 4.13 Shanghai RAAS
- 4.13.1 Shanghai RAAS Company Information
- 4.13.2 Shanghai RAAS Business Overview
- 4.13.3 Shanghai RAAS Pharmaceutical Excipient Albumin Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Shanghai RAAS Pharmaceutical Excipient Albumin Product Portfolio
- 4.13.5 Shanghai RAAS Recent Developments
- 4.14 Takeda
- 4.14.1 Takeda Company Information
- 4.14.2 Takeda Business Overview
- 4.14.3 Takeda Pharmaceutical Excipient Albumin Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Takeda Pharmaceutical Excipient Albumin Product Portfolio
- 4.14.5 Takeda Recent Developments
5 Global Pharmaceutical Excipient Albumin Market Scenario by Region
- 5.1 Global Pharmaceutical Excipient Albumin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Pharmaceutical Excipient Albumin Sales by Region: 2021-2032
- 5.2.1 Global Pharmaceutical Excipient Albumin Sales by Region: 2021-2026
- 5.2.2 Global Pharmaceutical Excipient Albumin Sales by Region: 2027-2032
- 5.3 Global Pharmaceutical Excipient Albumin Revenue by Region: 2021-2032
- 5.3.1 Global Pharmaceutical Excipient Albumin Revenue by Region: 2021-2026
- 5.3.2 Global Pharmaceutical Excipient Albumin Revenue by Region: 2027-2032
- 5.4 North America Pharmaceutical Excipient Albumin Market Facts & Figures by Country
- 5.4.1 North America Pharmaceutical Excipient Albumin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Pharmaceutical Excipient Albumin Sales by Country (2021-2032)
- 5.4.3 North America Pharmaceutical Excipient Albumin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Pharmaceutical Excipient Albumin Market Facts & Figures by Country
- 5.5.1 Europe Pharmaceutical Excipient Albumin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Pharmaceutical Excipient Albumin Sales by Country (2021-2032)
- 5.5.3 Europe Pharmaceutical Excipient Albumin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Pharmaceutical Excipient Albumin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Pharmaceutical Excipient Albumin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Pharmaceutical Excipient Albumin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Pharmaceutical Excipient Albumin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Pharmaceutical Excipient Albumin Market Facts & Figures by Country
- 5.7.1 South America Pharmaceutical Excipient Albumin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Pharmaceutical Excipient Albumin Sales by Country (2021-2032)
- 5.7.3 South America Pharmaceutical Excipient Albumin Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Pharmaceutical Excipient Albumin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Pharmaceutical Excipient Albumin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Pharmaceutical Excipient Albumin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Pharmaceutical Excipient Albumin Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Pharmaceutical Excipient Albumin Sales by Type (2021-2032)
- 6.1.1 Global Pharmaceutical Excipient Albumin Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Pharmaceutical Excipient Albumin Sales Market Share by Type (2021-2032)
- 6.2 Global Pharmaceutical Excipient Albumin Revenue by Type (2021-2032)
- 6.2.1 Global Pharmaceutical Excipient Albumin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Pharmaceutical Excipient Albumin Revenue Market Share by Type (2021-2032)
- 6.3 Global Pharmaceutical Excipient Albumin Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Pharmaceutical Excipient Albumin Sales by Application (2021-2032)
- 7.1.1 Global Pharmaceutical Excipient Albumin Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Pharmaceutical Excipient Albumin Sales Market Share by Application (2021-2032)
- 7.2 Global Pharmaceutical Excipient Albumin Revenue by Application (2021-2032)
- 7.2.1 Global Pharmaceutical Excipient Albumin Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Pharmaceutical Excipient Albumin Revenue Market Share by Application (2021-2032)
- 7.3 Global Pharmaceutical Excipient Albumin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Pharmaceutical Excipient Albumin Value Chain Analysis
- 8.1.1 Pharmaceutical Excipient Albumin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Pharmaceutical Excipient Albumin Production Mode & Process
- 8.2 Pharmaceutical Excipient Albumin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Pharmaceutical Excipient Albumin Distributors
- 8.2.3 Pharmaceutical Excipient Albumin Customers
9 Global Pharmaceutical Excipient Albumin Analyzing Market Dynamics
- 9.1 Pharmaceutical Excipient Albumin Industry Trends
- 9.2 Pharmaceutical Excipient Albumin Industry Drivers
- 9.3 Pharmaceutical Excipient Albumin Industry Opportunities and Challenges
- 9.4 Pharmaceutical Excipient Albumin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst